Latest Us Reimbursement News

Artrya has signed a five-year agreement with Huntsville Hospital Health System, converting the first participant in its SAPPHIRE Study into a commercial customer. The deal carries a minimum contracted value of US$0.5 million for Salix Coronary Anatomy, with further usage-based revenue possible from other modules.

Lumos Diagnostics has increased live FebriDx sites to 215 and moved two additional top 100 US urgent care groups into network rollout across more than 40 sites. Two further health-system-owned groups are validating the test across more than 45 sites, but the announcement does not disclose contract values or guaranteed purchase volumes.

4DMedical’s CT:VQ™ lung imaging technology secured FDA clearance and CMS reimbursement, driving rapid adoption in top US medical centres and expanding its addressable market to $3 billion with new clinical programs and European contracts.

ImpediMed reported a 15% revenue increase to $14.6 million in FY26, broadened reimbursement coverage for its SOZO platform to 95% of the US population, and launched new applications in heart health and weight management.

Tissue Repair advances its US Phase III chronic wound trial with 100 patients randomised and targets October FDA 510(k) submission. The company reports a robust cash position bolstered by R&D refunds and has cut manufacturing scale-up costs.

Rhythm Biosciences bolstered its financial position with a $5.2 million option underwriting while accelerating commercial adoption of its ColoSTAT® colorectal cancer test and advancing geneType™ partnerships internationally in Q4 FY26.

Adherium Limited has posted a fourth consecutive quarter of record remote patient monitoring revenue, driven by growing device activations and strong clinical evidence from the iCARE study, positioning the company for expanded value-based care contracts in the US.

ImpediMed reported a 3% revenue increase to $3.6 million in Q4 FY26, bolstered by a $15.3 million capital raise and strategic leadership hires as it pushes growth in cancer survivorship, heart health, and weight management.

PolyNovo has delivered solid FY26 revenue growth of 16.1%, driven by commercial sales expansion and improved manufacturing output, while progressing insurance recovery from its R&D centre fire.

Barramundi’s portfolio returned a solid 3.8% gross gain in Q2 2026, driven by strong AI-related infrastructure plays and takeover interest in key holdings, despite sector volatility and profit downgrades in healthcare and logistics.

Aroa Biosurgery delivered a breakout FY26 with NZ$104 million revenue, driven by strong Myriad sales and clinical trial success, setting the stage for ambitious FY27 growth.

Control Bionics advances its neural-signal technology across assistive communication, sports, and medical sectors, securing key US reimbursement and distribution agreements while broadening its international footprint.